Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) EBT Margin (2016 - 2025)

Haemonetics has reported EBT Margin over the past 17 years, most recently at 17.69% for Q4 2025.

  • Quarterly results put EBT Margin at 17.69% for Q4 2025, up 337.0% from a year ago — trailing twelve months through Dec 2025 was 17.23% (up 524.0% YoY), and the annual figure for FY2025 was 15.58%, up 398.0%.
  • EBT Margin for Q4 2025 was 17.69% at Haemonetics, up from 15.67% in the prior quarter.
  • Over the last five years, EBT Margin for HAE hit a ceiling of 21.4% in Q1 2025 and a floor of 12.17% in Q2 2021.
  • Median EBT Margin over the past 5 years was 13.02% (2023), compared with a mean of 10.88%.
  • Biggest five-year swings in EBT Margin: plummeted -2138bps in 2021 and later soared 1796bps in 2022.
  • Haemonetics' EBT Margin stood at 8.3% in 2021, then soared by 67bps to 13.83% in 2022, then dropped by -5bps to 13.09% in 2023, then rose by 9bps to 14.32% in 2024, then grew by 24bps to 17.69% in 2025.
  • The last three reported values for EBT Margin were 17.69% (Q4 2025), 15.67% (Q3 2025), and 14.05% (Q2 2025) per Business Quant data.